SUMMARY A double-blind crossover trial with 2-dimethylaminoethanol (Deanol), a possible precursor of brain acetylcholine, was carried out in nine patients with Huntington's chorea. It was found to be ineffective in inducing any alteration in hyperkinesia.
The pharmacological treatment of Huntington's chorea has been based on the use of neuroleptic drugs, on the hypothesis that there is a functional dopaminergic hyperactivity in this illness (Agid, 1975) .
More recently, after the observation of reduced cholinergic and GABAminergic activity at the striatal level in brains of choreic subjects (McGeer et al., 1973; Stahl and Swanson, 1974; Bird and Iversen, 1974) , therapeutic trials were carried out with substances which facilitate the formation and persistence of these supposed neurotransmitters.
The hypothesis of reduced cholinergic activity at the striatal level is supported by the therapeutic effectiveness of physostigmine, a powerful anticholinesterase drug which also passes the bloodbrain barrier (Aquilonius and Sjostrom, 1971; Klawans and Rubovitz, 1972; Davis et al., 1976) . Nevertheless, this drug cannot be used clinically because of serious and numerous side effects.
Since then, there have been attempts to influence cholinergic metabolism by providing substances considered to be acetylcholine precursors. Dimethylaminoethanol acid (Deanol), a drug which has been proved to enhance the formation of acetylcholine in the CNS, has been shown to have effects on the CNS in animals (Pfeiffer et al., 1957; Haubrich et al., 1975) , and in various pathological conditions in humans, such as schizophrenia, periodic headache, chronic states of fatigue, and bronchial asthma (Pfeiffer, 1958; Murphree et al., 1960) .
With regard to extrapyramidal pathology, dimethylaminoethanol has been used for therapy of Huntington's chorea and tardive dyskinesia. In Address for reprint requests: Dr T. A. Caraceni, Istituto Neurologico "C. Besta", Via Celoria 11, 20133 Milan, Italy. Accepted 13 June 1978 these syndromes cholinergic hypofunction is considered to be one of the principal factors causing the clinical manifestations (Klawans, 1973) .
The results obtained in tardive dyskinesia are ambiguous. In fact, some are positive (Miller, 1974; De Silva and Huang, 1975; Fann et al., 1975) , and others are completely negative (Crane, 1975; Escobar and Kemp, 1975) .
A clear-cut improvement in choreic abnormal movements was observed by Walker et al. (1973) during dimethylaminoethanol treatment of seven subjects with Huntington's chorea. At variance with this result, a worsening was described by Laterre and Fortemps (1975) (Table 1) .
The severity of hyperkinesia was evaluated from videotapes as described by Caraceni et al. (1977a) . Four neurologists assigned scores "blind" for four body territories (face, neck, trunk, and limbs) on a scale from 0 to 3, where 0 represented absence of hyperkinesia, and 1 to 3 graded its severity and persistence. The final rating was the sum of the scores given by the four examiners. The worst score was 48, the best, or normal, 0. Hyperkinetic states were considered mild for scores from 1 to 16, moderate from 17 to 32, and severe from 33 to 48. Intellectual impairment was evaluated on the Wechsler-Bellevue scale. Intelligence quotients (IQ) ranged between 61 and 92. Deterioration was present in almost all the cases. There was no rigidity in any patient. Three patients had bulimia, and one was anorexic. Psychiatric disturbances were exhibited as paranoid ideation in one patient who attempted suicide, and as depression in another. The values for weight and height are reported in Table 1 . The patients were studied in a double-blind crossover trial of dimethylaminoethanol and a placebo, with random choice of the initial drug made by the hospital pharmacist.
Previous drug therapies were haloperidol in four patients and N-(ethyl-2 pyrrolidinyl-methyl)-2-methoxy-5-sulphamoil-benzamide (sulpyride) in two. The daily dose of haloperidol was 4 mg for patients 1-3, and 6 mg for patients 2 and 6; and the duration of this treatment varied from six months to two years (Table 1) . Sulpyride was administered at a dose of 400 mg for six or 12 months (patients 7-9) ( Table 2 indicates the hyperkinesia scores under the various conditions of the pharmacological trials under basal conditions, after placebo, and with the maximum dose of dimethylaminoethanol. Statistical analysis did not reveal any significant difference between therapy-free versus placebo, therapy-free versus dimethylaminoethanol, or placebo versus dimethylaminoethanol. The analysis of the results for each individual patient suggests there was an improvement in the hyperkinesia after treatment of five cases with dimethylaminoethanol. However, with the exception of case 4, where a notable improvement was observed, the therapeutic effect was small, modifications of the scores under different therapies being less than 25%.
In Table 3 , the hyperkinetic scores of the four patients who received haloperidol therapy before the double-blind study were compared with those during dimethylaminoethanol treatment and 
Discussion
This pharmacologic trial of dimethylaminoethanol (Deanol) in the treatment of Huntington's chorea has shown no useful activity of the drug. In fact, the statistical analysis of paired data in nine cases did not demonstrate any significant difference in hyperkinetic symptoms between basal conditions and active therapy, or between the scores obtained while on placebo or dimethylaminoethanol. Furthermore, no therapeutic effect was observed in the individual cases, comparing the scores before and after dimethylaminoethanol, except for case 4 in whom the difference in the scores was greater, while a significant reduction of hyperkinesia had been induced by haloperidol treatment in four cases. These results confirm our previous observations on the effects of physostigmine and haloperidol (Caraceni et al., 1977b) , and contradict the observations of Walker et al. (1973) who obtained positive results in five of seven patients with Huntington's chorea, using doses similar to those administered by us.
Our data do not support the concept of reduced activity of choline acetyltransferase in the basal ganglia in Huntington's chorea. The hypothesis of reduced cholinergic tone in Huntington's chorea is supported by the evidence of low cerebrospinal fluid choline levels (Aquilonius et al., 1975; Consolo et al., 1977) , by the therapeutic effectiveness of cholinesterase inhibitors, and by the clinical worsening observed during anticholinergic treatment .
The disagreement between the theoretical data and our present results may be explained as follows.
Firstly, the dosage used by us may be insufficient to furnish the quantity of precursor necessary to provoke a valid modification in CNS levels of acetylcholine. On the other hand, the doses of dimethylaminoethanol which we used were perfectly comparable to those adopted by other workers. It seems to us that the data reported in the literature on the effectiveness of cholinomimetic substances in choreic hyperkinesia are not convincing and, in fact, the results ascribed to physostigmine are not always concordant (Tarsy et al., 1974 (Pepeu et al., 1960; Weiner et al., 1976 Furthermore, the reduction in activity of choline acetyltransferase was not verified in the brains of all the choreic patients, but only in 23 out of 37 cases by Bird and Iversen (1974) . This observation would account for a certain diversity in responsiveness recorded in different studies.
As many different enzymes may be involved or impaired in Huntington's chorea, for instance glutamic acid decarboxylase, and angiotensin converting enzyme (Arregui et al., 1977) , and as there are interactions between the different neurotransmitters, it is possible that treatment with a medication which acts solely on the cholinergic system would be unable to induce detectable results.
